Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

318 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daratumumab for POEMS Syndrome.
Khan M, Stone K, van Rhee F. Khan M, et al. Among authors: van rhee f. Mayo Clin Proc. 2018 Apr;93(4):542-544. doi: 10.1016/j.mayocp.2018.02.001. Mayo Clin Proc. 2018. PMID: 29622102 No abstract available.
Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A, Thuro B, Melenhorst J, Barrett J, Shaughnessy J, Old LJ, Barlogie B, Brichard VG, van Rhee F. Szmania S, et al. Among authors: van rhee f. J Immunother. 2007 Nov-Dec;30(8):847-54. doi: 10.1097/CJI.0b013e318158fcff. J Immunother. 2007. PMID: 18049337
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.
Moreno-Bost A, Szmania S, Stone K, Garg T, Hoerring A, Szymonifka J, Shaughnessy J Jr, Barlogie B, Prentice HG, van Rhee F. Moreno-Bost A, et al. Among authors: van rhee f. Cytotherapy. 2011 May;13(5):618-28. doi: 10.3109/14653249.2010.529893. Epub 2010 Dec 20. Cytotherapy. 2011. PMID: 21171821 Free PMC article.
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels.
Stone K, Woods E, Szmania SM, Stephens OW, Garg TK, Barlogie B, Shaughnessy JD Jr, Hall B, Reddy M, Hoering A, Hansen E, van Rhee F. Stone K, et al. Among authors: van rhee f. PLoS One. 2013;8(1):e54610. doi: 10.1371/journal.pone.0054610. Epub 2013 Jan 23. PLoS One. 2013. PMID: 23372742 Free PMC article.
Siltuximab for multicentric Castleman disease.
Liu YC, Stone K, van Rhee F. Liu YC, et al. Among authors: van rhee f. Expert Rev Hematol. 2014 Oct;7(5):545-57. doi: 10.1586/17474086.2014.946402. Epub 2014 Aug 9. Expert Rev Hematol. 2014. PMID: 25110138
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F. Szmania S, et al. Among authors: van rhee f. J Immunother. 2015 Jan;38(1):24-36. doi: 10.1097/CJI.0000000000000059. J Immunother. 2015. PMID: 25415285 Free PMC article. Clinical Trial.
Treatment of Idiopathic Castleman Disease.
van Rhee F, Greenway A, Stone K. van Rhee F, et al. Hematol Oncol Clin North Am. 2018 Feb;32(1):89-106. doi: 10.1016/j.hoc.2017.09.008. Hematol Oncol Clin North Am. 2018. PMID: 29157622 Free article. Review.
Infectious and immunological sequelae of daratumumab in multiple myeloma.
Johnsrud AJ, Johnsrud JJ, Susanibar SA, Kamimoto JJ, Kothari A, Burgess M, Van Rhee F, Rico JC. Johnsrud AJ, et al. Among authors: van rhee f. Br J Haematol. 2019 Apr;185(1):187-189. doi: 10.1111/bjh.15433. Epub 2018 Jul 5. Br J Haematol. 2019. PMID: 29974956 Free article. No abstract available.
318 results